A Randomized Controlled Trial Comparing Botulinum Toxin Type A Xeomin ® and Dysport ® for Treatment Of Primary Axillary Hyperhidrosis (P3.021) (original) (raw)

Neurology, 2014

Abstract

BACKGROUND IncobotulinumtoxinA (Xeomin ®), a botulinum toxin type A drug without complexing proteins, became available in 2005. To our knowledge, this is the first randomized controlled double blind trial comparing the therapeutic effect of two non-bioequivalent toxins: IncobotulinumtoxinA and AbobotulinumtoxinA (Dysport ®) for treatment of primary axillary hyperhidrosis. METHODS: Twenty patients with primary axillary hyperhidrosis were treated with IncobotulinumtoxinA injections into one axilla and AbobotulinumtoxinA injections into the other axilla. Both patients and the physician were blinded as to which axilla received which of the two toxins. IncobotulinumtoxinA, 100 IU, and AbobotulinumtoxinA, 500IU, were diluted in 5 mL of 0.9% saline each. A total of 50 IU of IncobotulinumtoxinA or 250IU of AbobotulinumtoxinA was injected. Pain at the injection site has been evaluated by the VAS scale. A twelve month follow up is scheduled to evaluate the difference between these two toxins ...

Francesca Pastorelli hasn't uploaded this paper.

Let Francesca know you want this paper to be uploaded.

Ask for this paper to be uploaded.